Revvity was listed on the New York Stock Exchange, and TD Cowen subsequently restated its buy rating on the company's shares.
2 reports, 2 independent
Updated Aug 4
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Revvity was listed on the New York Stock Exchange, and TD Cowen subsequently restated its buy rating on the company's shares.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
Related events
- TD Cowen issued a buy rating and price target for Evolv Technologies Holdings, Inc.
- TD Cowen upgraded Crescent Biopharma shares to 'strong-buy', while Wedbush reiterated 'outperform', and a CEO sold shares under a 10b5-1 plan.
- Investment bank TD Cowen issued buy rating reports and upgraded the stock rating for Danaher, which is tracked by MarketBeat.
- TD Cowen provided analyst ratings and price targets for Ardelyx, accompanied by required stock transaction filings with the SEC.
- Raymond James Financial and TD Cowen issued rating updates for GDS, alongside an insider transaction disclosure filed with the SEC.